"We found that the guggulipid product did not lower the level of LDL-C (low density lipoprotein cholesterol) in our trial participants, but actually raised LDL-C slightly," said Philippe O. Szapary, MD, Assistant Professor of Medicine at Penn and principal author of the study. Low-density lipoprotein can lead to heart disease by accumulating on arterial walls. It is often identified as "bad" cholesterol by researchers in order to distinguish it from high-density lipoprotein (HDL), the "good" cholesterol that keeps arteries clear.
The randomized, double-blind, eight-week study at Penn included 103 volunteers who were divided into three groups. One group was given a standard dose (1,000 mg) of guggulipid three times daily; a second group was given a high dose (2,000 mg) of the extract; and the third group was given the placebo.
"We found LDL-C increased by four percent in the standard-dose group and five percent in the high-dose group. At the same time, it decreased by five percent in the placebo group," Szapary said.
Further, "a small subset of patients taking the herb developed a rash indicating they were experiencing hypersensitivity drug reactions," Szapary said. The rash disappeared when they stopped taking the supplement.
"Our findings do not support the use of gugglipid to control LDL-C in the general population," Szapary said. "The results do strengthen our belief that dietary supplements need to be studied in a rigorous way, to test both their safety and their efficacy." He is extending his study to investigate further the effects of guggulipid on triglycerides, also called "blood fats," and inflammation, both of which appeared to be more responsive than cholesterol to the effects of the herb in the clinical study.
Guggulipid, a substance derived from one of the fabled myrrh plants of the Middle East, has a 2,600-year tradition in traditional medicine. Indian practitioners of ayuvedic medicine have used the herb in holistic regimens combining meditation, yoga and diet to treat obesity, atherosclerosis, high cholesterol and arthritis. In the Christian tradition, the bitter-tasting, fragrant myrrh, which is used in incense and perfume, was presented as a gift from the three wise men to the infant Jesus.
Szapary was assisted in the study by Megan L. Wolf, BS; LeAnne T. Bloedon, MS, RD; Andrew J. Cucchiara, PhD; Ara H. DerMarderosian, PhD; Michael D. Cirigliano, MD; and Daniel Rader, MD, all of Penn.
The study was funded by the National Center for Complementary and Alternative Medicine at the National Institutes of Health, and the Sabinsa Corporation, manufacturer of a guggulipid extract product.
Editor's note: None of the study investigators has any financial interest in the Sabinsa Corp.
This release may also be found online at: www.uphs.upenn.edu/news.
PENN Medicine is a $2.2 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System (created in 1993 as the nation's first integrated academic health system).
Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
Penn Health System consists of four hospitals (including its flagship Hospital of the University of Pennsylvania, consistently rated one of the nation's "Honor Roll" hospitals by U.S. News & World Report), a faculty practice plan, a primary-care provider network, three multispecialty satellite facilities, and home health care and hospice.